GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » Total Equity

Asymchem Laboratories Tianjin Co (HKSE:06821) Total Equity : HK$18,437 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Asymchem Laboratories Tianjin Co Total Equity?

Asymchem Laboratories Tianjin Co's total equity for the quarter that ended in Mar. 2025 was HK$18,437 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Asymchem Laboratories Tianjin Co Total Equity Historical Data

The historical data trend for Asymchem Laboratories Tianjin Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asymchem Laboratories Tianjin Co Total Equity Chart

Asymchem Laboratories Tianjin Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,100.44 15,440.55 17,526.84 19,152.05 18,003.70

Asymchem Laboratories Tianjin Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19,126.47 17,712.42 18,313.95 18,003.70 18,436.86

Asymchem Laboratories Tianjin Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Asymchem Laboratories Tianjin Co's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=20593.855-2590.155
=18,004

Asymchem Laboratories Tianjin Co's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=20851.532-2414.677
=18,437

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asymchem Laboratories Tianjin Co Total Equity Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Asymchem Laboratories Tianjin Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » Total Equity
Comparable Companies
SHSE:688266 SZSE:301301 SZSE:002007 SHSE:688278 SHSE:688166 SHSE:603233 SZSE:300255 BJSE:832982 SHSE:688336 SHSE:688520 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
7K90:Germany 002821:China
Address
No. 6 Dongting Third Street, Economic and Technological Development Zone, Tianjin, CHN, 300457
Website
https://www.asymchem.com
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development manufacturing organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing which focuses on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Schroders Plc 2102 Investment manager
Norges Bank 2101 Beneficial owner
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Springhill Fund Asset Management (hk) Company Limited 2102 Investment manager
Springhill Fund Limited 2201 Interest of corporation controlled by you
Springhill Global Feeder Fund Limited 2201 Interest of corporation controlled by you
Springhill Master Fund Limited 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Jpmorgan Asset Management (asia Pacific) Limited 2102 Investment manager
Fidelity Management & Research Company Llc

Asymchem Laboratories Tianjin Co Headlines

No Headlines